RNF43 Truncations Trap CK1 to Drive Niche-independent Self-renewal in Cancer
Overview
Molecular Biology
Authors
Affiliations
Wnt/β-catenin signaling is a primary pathway for stem cell maintenance during tissue renewal and a frequent target for mutations in cancer. Impaired Wnt receptor endocytosis due to loss of the ubiquitin ligase RNF43 gives rise to Wnt-hypersensitive tumors that are susceptible to anti-Wnt-based therapy. Contrary to this paradigm, we identify a class of RNF43 truncating cancer mutations that induce β-catenin-mediated transcription, despite exhibiting retained Wnt receptor downregulation. These mutations interfere with a ubiquitin-independent suppressor role of the RNF43 cytosolic tail that involves Casein kinase 1 (CK1) binding and phosphorylation. Mechanistically, truncated RNF43 variants trap CK1 at the plasma membrane, thereby preventing β-catenin turnover and propelling ligand-independent target gene transcription. Gene editing of human colon stem cells shows that RNF43 truncations cooperate with p53 loss to drive a niche-independent program for self-renewal and proliferation. Moreover, these RNF43 variants confer decreased sensitivity to anti-Wnt-based therapy. Our data demonstrate the relevance of studying patient-derived mutations for understanding disease mechanisms and improved applications of precision medicine.
Mechanistic insights into Wnt-β-catenin pathway activation and signal transduction.
Maurice M, Angers S Nat Rev Mol Cell Biol. 2025; .
PMID: 39856369 DOI: 10.1038/s41580-024-00823-y.
Lack of dominant-negative activity for tumor-related ZNRF3 missense mutations at endogenous levels.
Li S, Niu J, Zhang R, Massaar S, Neves Cabrita M, van Merode J Oncogene. 2024; .
PMID: 39674817 DOI: 10.1038/s41388-024-03253-4.
Wang X, Qu Z, Zhao S, Luo L, Yan L Mol Med. 2024; 30(1):193.
PMID: 39468464 PMC: 11520425. DOI: 10.1186/s10020-024-00957-x.
New Target(s) for RNF43 Regulation: Implications for Therapeutic Strategies.
Nag J, Appasamy P, Malka H, Sedley S, Bar-Shavit R Int J Mol Sci. 2024; 25(15).
PMID: 39125653 PMC: 11311281. DOI: 10.3390/ijms25158083.
van der Graaff D, Seghers S, Vanclooster P, Deben C, Vandamme T, Prenen H Cancers (Basel). 2024; 16(15).
PMID: 39123399 PMC: 11311786. DOI: 10.3390/cancers16152671.